Save for clinic
📖 Full analysis: Desktop version — complete efficacy tables, safety detail, subgroup data, and clinical implications
⚠️ Updated analysis. The primary endpoint (investigator-assessed PFS) was previously reported. This analysis reports overall survival at 44.8 months median follow-up.
🎯 Clinical Bottom Line
Palbociclib plus fulvestrant doubled progression-free survival over fulvestrant alone in women with HR-positive, HER2-negative advanced breast cancer progressing on prior endocrine therapy. With nearly four years of follow-up, overall survival was numerically longer with the combination but did not meet the prespecified significance threshold — the trial was powered for PFS, not OS.
Key Result (OS, ITT): Median OS 34.9 vs 28.0 months — HR 0.81 (95% CI 0.64–1.03; P=0.09) — did not meet prespecified threshold of P=0.047
Safety Signal: Grade 3 or 4 neutropenia in 70% of palbociclib-treated patients; febrile neutropenia remained uncommon at 1%.
✅ Patient Eligibility
Must Have:
- HR-positive, HER2-negative advanced breast cancer
- Disease progression after previous endocrine therapy
- Any menopausal status (premenopausal patients require concurrent goserelin)
Cannot Have:
- Key exclusion criteria not reported in this publication — refer to full trial protocol (NCT01942135)
💊 Dosing Quick Guide
Experimental Regimen
Palbociclib: 125 mg orally once daily, days 1–21 of 28-day cycle Fulvestrant: 500 mg IM every 14 days × 3 injections, then every 28 days Duration: Until progression or unacceptable toxicity
Control Regimen
Placebo: orally once daily, days 1–21 of 28-day cycle Fulvestrant: 500 mg IM every 14 days × 3 injections, then every 28 days
Key Dose Modifications [2]
- Dose reduction levels: 125 mg → 100 mg → 75 mg
- Hold for: ANC <1,000/mm³ on day 1 of a cycle; resume when ANC ≥1,000/mm³
- Monitoring: CBC before each cycle and on day 15 of first 2 cycles
Mechanism: Palbociclib is an oral CDK4/6 inhibitor that blocks retinoblastoma protein phosphorylation, arresting tumor cells in G1 phase and preventing cell-cycle progression [2].
⚠️ Safety Snapshot
| Grade 3 or 4 Toxicities | Palbociclib–Fulvestrant (n=345) | Placebo–Fulvestrant (n=172) |
|---|---|---|
| Neutropenia | 70% | 0% |
| Infections | 5% | 3% |
| Anemia | 4% | 2% |
| Thrombocytopenia | 3% | 0% |
| Fatigue | 3% | 1% |
| AST elevation | 3% | 2% |
| Febrile neutropenia | 1% | 0% |
⚠️ Neutropenia: Grade 3 or 4 in 70%. Febrile neutropenia in only 1% (3/345 patients). Monitor CBC rigorously; dose modifications per label [2].
📊 Key Numbers
Median follow-up: 44.8 months
| Outcome | Palbociclib–Fulvestrant | Placebo–Fulvestrant | HR (95% CI) | p-value |
|---|---|---|---|---|
| PFS (primary, previously reported) | 11.2 mo | 4.6 mo | 0.50 (0.40–0.62) | — |
| OS (key secondary) | 34.9 mo | 28.0 mo | 0.81 (0.64–1.03) | P=0.09 |
| Time to chemotherapy (exploratory) | 17.6 mo | 8.8 mo | 0.58 (0.47–0.73) | P<0.001 |
| Time to end of next therapy line (exploratory) | 18.8 mo | 14.1 mo | 0.68 (0.56–0.84) | P<0.001 |
OS prespecified significance threshold was P=0.047; trial powered for PFS, not OS.
🔬 Key Comparator Context
| Trial | Regimen | Population | Primary Endpoint | Key Result | Ref |
|---|---|---|---|---|---|
| PALOMA-3 | Palbociclib + fulvestrant | HR+/HER2− ABC, post-ET progression | PFS | mPFS 11.2 vs 4.6 mo; HR 0.50. mOS 34.9 vs 28.0 mo; HR 0.81 (P=0.09) | [1] |
| MONALEESA-3 | Ribociclib + fulvestrant | HR+/HER2− ABC, 1L or 2L | PFS | mPFS 20.5 vs 12.8 mo; HR 0.593. mOS 53.7 vs 41.5 mo; HR 0.73 (P=0.004) | [4] |
| MONARCH 2 | Abemaciclib + fulvestrant | HR+/HER2− ABC, post-ET progression | PFS | mPFS 16.4 vs 9.3 mo; HR 0.553. mOS 46.7 vs 37.3 mo; HR 0.757 (P=0.0137) | [5] |
Cross-trial comparisons are limited by differences in populations, designs, and endpoints.
🔍 Subgroups to Watch
Endocrine-sensitive (n=410): HR 0.72 (0.55–0.94) — benefit concentrated in endocrine-sensitive patients Not endocrine-sensitive (n=111): HR 1.14 (0.71–1.84) — no OS benefit observed; interaction P=0.12 Age ≥65 yr (n=129): HR 0.52 (0.33–0.82) — strongest benefit by age; interaction P=0.04 Postmenopausal (n=413): HR 0.73 (0.57–0.95) — clear benefit Pre/perimenopausal (n=108): HR 1.07 (0.61–1.86) — no OS separation; interaction P=0.25
Subgroup analyses were not powered for formal comparisons. Results are hypothesis-generating.
📋 Regulatory Status
| Region | Status |
|---|---|
| FDA | Approved: HR+/HER2− advanced/metastatic breast cancer with fulvestrant after prior ET [2] |
| EMA | Approved: HR+/HER2− locally advanced/metastatic breast cancer with fulvestrant |
⚠️ Verify current regulatory status before prescribing.
NCCN: Palbociclib + fulvestrant is a preferred regimen for HR+/HER2− recurrent/metastatic breast cancer, 2L+ endocrine therapy (Category 1) [3]
⚡ Grey Zones
- No head-to-head data comparing palbociclib, ribociclib, and abemaciclib — OS differences across trials may reflect design limitations, not drug differences
- Patients without documented endocrine sensitivity showed no OS benefit (HR 1.14) — optimal treatment for this subgroup is uncertain
- Most current patients receive CDK4/6 inhibitors first-line; PALOMA-3 enrolled CDK4/6 inhibitor–naïve patients — applicability to current sequencing questions is limited
- Premenopausal subgroup showed no OS separation — whether this population benefits equally remains unclear
- Trial powered for PFS, not OS; 60% data maturity with ~46% power for OS may have been insufficient to detect a true survival benefit
📖 Full Analysis
Read the complete desktop article with full efficacy tables, safety detail, subgroup data, comparator trials, and clinical implications at kill-cancer.com
About the Author
Andrew Stevenson is the founder and systems architect of kill-cancer.com. He holds 17 Google technical certifications in data systems, automation, and applied AI — the engineering foundation behind the extraction and verification pipeline that produces every article on this platform. Every number traces to its source publication. Zero calculation. Zero editorializing. Zero hallucination. Five siblings lost to cancer built the urgency. The engineering builds the trust.
📧 andrew@kill-cancer.com 🌐 kill-cancer.com 💬 kill-cancer.com/forum
For healthcare professionals only. Not medical advice. Trial results are presented as reported in the source publication. Updated data, label changes, or guideline revisions published after the source article may alter clinical applicability. Consult FDA labeling, NCCN guidelines, and institutional protocols.
References
- Turner NC, Slamon DJ, Ro J, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926-1936. doi:10.1056/NEJMoa1810527
- Ibrance (palbociclib) prescribing information. U.S. Food and Drug Administration. Accessed March 2026.
- NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026. Accessed March 2026.
- Slamon DJ, Neven P, Chia S, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514-524. doi:10.1056/NEJMoa1911149
- Sledge GW Jr, Toi M, Neven P, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2. JAMA Oncol. 2020;6(1):116-124. doi:10.1001/jamaoncol.2019.4782